Kindred Biosciences, Inc. (KIN) saw its loss narrow to $5.81 million, or $0.29 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $6.42 million, or $0.31 a share.

The company has not recorded any revenues for the current as well as previous quarter.

Operating loss for the quarter was $5.91 million, compared with an operating loss of $6.46 million in the previous year period.

"We are very pleased with the progress of Mirataz and Zimeta, including the recently announced approval of the efficacy technical section for Mirataz," stated Richard Chin, M.D., president and chief executive officer of KindredBio. "We are looking forward to the transition to a commercial-stage company in 2017, with the anticipated approval and launch of two products in the second half of the year, assuming that the regulatory review proceeds as expected. Zimeta (for the control of fever in horses) and Mirataz (for the management of weight loss in cats) are expected to be the first products approved by the Food and Drug Administration for their respective indications. Our robust cash position supports our deep pipeline, with readouts from multiple pilot studies and the initiation of additional pivotal studies expected this year. In addition, our state-of-the art GMP biologics manufacturing plant is in the final stages of commissioning, which will mark an important milestone for our biologics program."